<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985007</url>
  </required_header>
  <id_info>
    <org_study_id>SZCDIAG</org_study_id>
    <nct_id>NCT03985007</nct_id>
  </id_info>
  <brief_title>CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Chidamide, Decitabine Combined With Priming IAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the therapeutic efficacy and side effect of chidamide,
      decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid
      leukemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Rate</measure>
    <time_frame>1 month</time_frame>
    <description>Remission rate achieved after one-two couses induction therapy by CDIAG regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survial</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events in hematological system</measure>
    <time_frame>1 month</time_frame>
    <description>Record of adverse events in hematological system during and after CDIAG regimen induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in other organs or systems</measure>
    <time_frame>1 month</time_frame>
    <description>Record of adverse events in other organs or systmes during and after CDIAG regimen induction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Acute Myeloid Leukemia, Relapsed, Adult</condition>
  <arm_group>
    <arm_group_label>CDIAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDIAG regimen</intervention_name>
    <description>Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.</description>
    <arm_group_label>CDIAG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory acute myeloid leukemia patients without severe complications
             such as active infections and bleedings; ECOG score less than 3.

        Exclusion Criteria:

          -  Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Li Xue, M.D.</last_name>
    <phone>+86 512 67781139</phone>
    <email>slxue@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Li Xue, M.D.</last_name>
      <phone>+86 512 6778 1139</phone>
      <email>slxue@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Sheng-Li Xue, MD</investigator_full_name>
    <investigator_title>accociate professor</investigator_title>
  </responsible_party>
  <keyword>chidamide</keyword>
  <keyword>decitabine</keyword>
  <keyword>priming regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

